Increase: 280,714 results found.
 |
Increase My Education
Search degreehorizon.com and start the exciting process of getting your associates, bachelors, masters, or doctorate degree online from an accredited distance learning college or university today!
Increasemyeducation.com ~
Site Info
Whois
Trace Route
RBL Check
|
 |
Find Your HER2+ Breast Cancer Support Community - Herceptin® (trastuzumab)
Find a number of different avenues for which to connect with a large community also dealing with HER2+ breast cancer. Who is Herceptin for? Breast Cancer. Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2+ and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high risk feature.† Herceptin can be used in several different ways: As part of a treatment course including the chemotherapy drugs Adriamycin® (doxorubicin), Cytoxan® (cyclophosphamide), and either Taxol® (paclitaxel) or Taxotere® (docetaxel). This treatment course is known as 'AC→TH'; With the chemotherapy drugs Taxotere and Paraplatin® (carboplatin). This treament course is known as 'TCH'; Alone after treatment with multiple other therapies, including an anthracycline (Adriamycin)-based therapy (a type of chemotherapy). † High-risk is defined as ER/PR positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3. Herceptin has 2 approved uses in metastatic breast cancer: Herceptin in combination with the chemotherapy drug Taxol® (paclitaxel) is approved for the first line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer; Herceptin alone is approved for the treatment of HER2+ breast cancer in patients who have received one or more chemotherapy courses for metastatic disease. Metastatic Stomach Cancer. Herceptin is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2+ metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease. Adriamycin is a registered trademark of Pharmacia Inc. Cytoxan, Taxol and Paraplatin are registered trademarks of Bristol-Myers Squibb Company. Taxotere is a registered trademark of sanofi-aventis U.S. LLC. Serious Side Effects. Herceptin treatment can result in heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure). The risk and seriousness of these heart problems were highest in people who received both Herceptin and a certain type of chemotherapy (anthracycline). One patient died in an adjuvant (early) breast cancer trial of significantly weakened heart muscle; Your doctor will evaluate your heart function before and during treatment. For adjuvant breast cancer therapy, your doctor will also evaluate heart function after the end of treatment. Your doctor will stop Herceptin therapy if you have serious weakening of the heart muscle or changes in the heart muscle structure; Some patients have had serious infusion reactions and lung problems; infusion reactions leading to death have been reported. Your doctor may have you completely stop Herceptin treatment if you have a severe allergic reaction, swelling, lung problems, swelling of the lungs, or severe shortness of breath; Herceptin can cause harm to the fetus (unborn baby), in some cases death of the fetus, when taken by a pregnant woman. Please see the full Prescribing Information at www.gene.com/gene/products/information/pdf/herceptin-prescribing.pdf for Serious Side Effects and additional important safety information.
Herstory.com ~
Site Info
Whois
Trace Route
RBL Check
|
|
|
|
Site Info
